[Multimodality treatment for hepatocellular carcinoma].

Area of Science:

• Hepatology
• Oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• In Germany, HCC predominantly arises from chronic liver diseases like alcohol abuse and viral hepatitis, progressing through liver cirrhosis.
• Despite advancements in understanding HCC's pathophysiology, patient prognosis remains largely unfavorable.

Purpose of the Study:

• To summarize the current understanding and management of hepatocellular carcinoma.
• To highlight the role of interdisciplinary approaches and emerging systemic therapies in HCC treatment.
• To project future improvements in HCC patient prognosis through structured treatment algorithms and advanced pharmacotherapy.

Main Methods:

• Review of current literature on hepatocellular carcinoma etiology, pathophysiology, and treatment.
• Analysis of the impact of interdisciplinary patient management involving internists, surgeons, and radiologists.
• Evaluation of the role of systemic therapies targeting specific biological pathways in HCC.

Main Results:

• Chronic liver disease is the primary driver of hepatocellular carcinoma in Germany.
• Interdisciplinary collaboration facilitates effective palliative care for HCC patients.
• Systemic therapies targeting HCC's biological processes show promise for improving treatment efficacy.

Conclusions:

• While understanding of HCC has grown, prognosis remains poor for many patients.
• Integrated, interdisciplinary management combined with advanced systemic therapies is crucial for effective HCC treatment.
• Adherence to defined treatment protocols and improved drug therapies are expected to enhance future HCC patient outcomes.